2023-12-11 13:00:00 Merck KGaA provided an update on phase III studies evaluating evobrutinib for the treatment of relapsing multiple sclerosis (MS). Neither trial met its primary endpoints. Among these criteria, the reduction in annualized relapse rates compared to oral teriflunomide, the reference treatment. “With evobrutinib, our goal was to address the significant unmet need in … Read more
At the 2023 JP Morgan Healthcare Conference, there is no news of large-scale M&A (mergers and acquisitions) compared to previous years, and global big pharmas are expected to introduce new products and promising pipelines in preparation for patent expiration. According to Kiwoom Securities’ ‘JP Morgan Healthcare Conference Summary’ report, this JP Morgan Healthcare Conference, which … Read more
The American laboratory Merck estimated that this year it will obtain up to USD 6,000 million in sales of its pill against coronavirus (COVID-19), molnupiravir, according to a financial report published on Thursday. The US pharmaceutical company said it generated $952 million from the sale of its oral COVID-19 pill in the fourth quarter of … Read more